The patient with cervical cancer is usually asymptomatic in the early stages. The history and physical must include sexual history including the age of first sexual encounter. Sexual history includes questions about postcoital bleeding and pain during intercourse. The history includes questioning about previous sexually transmitted infections, the number of lifetime partners, previous history of HPV infection, history of human immunodeficiency virus, use of tobacco, and whether the patient has had a previous vaccination against HPV. Women should be asked about menstrual patterns and any abnormal bleeding, persistent vaginal discharges, irritations, or known cervical lesions. The physical exam must include a full evaluation of the external and internal genitalia. In women with cervical cancer, the exam findings might include a friable cervix, lesions, erosions, or bleeding with examination and fixed adnexa.

According to the United States Preventative Services Task Force (USPTF), Pap screening is recommended beginning at age 21 years of age. HPV testing begins at age 30 in conjunction with Pap smear cytology. Screening is recommended every three years for women with continued normal screening and those low risk for cervical cancer. For women over 30 years of age, cytology can be every five years with HPV testing. Level A recommendation or women with low-risk status and consistent normal screenings can discontinue cervical cancer cytology and HPV testing at age 65. Women who have had a total abdominal hysterectomy including removal of the cervix for benign disease do not require further screening.[4]

Precancerous lesions are managed conservatively for those women younger than 25 years. The majority of abnormal findings in women younger than 25 are low-risk cervical dysplasia and will resolve spontaneously. Colposcopy evaluates persistent, abnormal cytology or lesions suspected to be greater than low risk. These are managed according to findings. Low-risk lesions may be watched and reevaluated more frequently, and high-risk lesions are treated based on size, location, and staging. Cryotherapy or excision is done to manage pre-cancerous lesions that are limited in size and depth. Conization, laser or Loop Electrosurgical Excision Procedure (LEEP) are used in managing those lesions that include the endocervical canal and are more extensive. LEEP may provide better visualization of the squamocolumnar junction and provide the benefit of less bleeding in the outpatient setting. [12] If cancer is diagnosed, the next step in management is staging to determine further treatment. Staging is based on findings and results from examination, tissue findings, imaging, and reported signs and symptoms. Grading is based on the size and depth of cancer and signs of spread to other organs. Treatment of early-stage disease includes a radical hysterectomy. For women who desire pregnancy with early-stage disease, conization may be the initial treatment. Chemotherapy and radiation are usually the next steps in treatment after hysterectomy to slow the growth of cancer.

Evaluating visible cervical lesions for cervical cancer is important. However, most cervical cancer will not present with an overt mass in early stages and as discussed above is asymptomatic. Other possible causes of cervical lesions or abnormal bleeding include sexually transmitted infections, cervical fibroids, endometriosis, and cervical polyps. Diagnosis may require further testing and evaluation of symptoms to determine whether the disease is related to cervical cancer. In some cases, diagnostic biopsy is needed to finalize the diagnosis. Rarely, metastatic cancer may be identified on the uterine cervix during a routine pap smear.[13]

The estimated effectiveness of HPV vaccination is 90 percent. [14] Inconsistent screening is an independent risk factor for the late diagnosis of cervical cancer. [15] The five-year survival rate for cervical cancer can approach 92 percent. The higher stage at presentation decreases survival and increases the chance of recurrence. African American women tend to have the highest mortality and lowest survival rate. The survival rate may be less than 50 percent. Contributing factors to differences in outcomes may include differences in the delivery of evidence-based care, later stage of diagnosis, lymph node spreading, age, and size and invasion of the tumor at the time of diagnosis. [10][16]

Complications of advanced disease and associated treatments are similar to other cancers. Complications may include renal failure, hydronephrosis, pain, lymphedema, bleeding disorder, and fistulas. [17] Rare sequelae may include orbital index and blindness. [18]

Both traditional methods of patient education and innovative methods can increase awareness of cervical cancer and the need for prevention and early screening. [19][20] The literature shows that doctors may not be recommending or discussing HPV vaccination with patients. Women and parents also have vaccination fears. In high-risk populations, additional education to physicians may increase awareness, prevention, and screening among those women at risk for highest mortality.[21]  Although, a patient may prefer health system education from the provider. Additional education including culturally sensitive information, appropriate language to reach low health literacy populations, and targeted efforts to women not yet sexually active are needed to expand patient education and awareness of cervical cancer prevention and screening beyond the clinical setting through community outreach. [22][23]

Primary prevention includes vaccination to prevent cervical cancer. There is a quadrivalent vaccine that prevents not only cervical cancer but also prevents genital warts. The recommended age for vaccination is from 9 to 45 years old for females. It is approved for females ages 9 to 45 and is also recommended for males. Health promotion aimed at vaccination can have a major impact on cervical cancer mortality in women in low resource areas and those who are in high-risk ethnic groups. A vaccine that only covers HPV 16 and 18 is no longer marketed in the United States. However, its use may continue in other areas outside of the United States.

The interprofessional team care in the prevention, screening, treatment, and management of cervical cancer can improve awareness, screening, and management of cervical cancer. The use of pubic education can increase awareness about cervical cancer prevention and screening and the importance of identifying precancerous lesions. [24][25][26] Primary care providers performing cervical cancer screening, colposcopies, and LEEP procedures, must have ongoing dialogues with gynecology about findings, suspicious lesions, outcomes, and management and treatment. Organized protocols and guidelines across the system can lead to better outcomes in increasing awareness, screening, management and treatment, and follow-up. Developing a culturally sensitive system directed at increasing patient-centered education will also require the input of diverse staff and providers with language skills, cultural competency, lab, and nursing.

The interprofessional team can optimize the treatment of patients through communication and coordination of care. Primary care physicians, gynecologists, radiation oncologists, and nurse practitioners provide diagnoses and care plans. Specialty care ambulatory care and oncology nurses should work with the team for coordination of care and are involved in patient education. They should provide feedback to the rest of the team. Pharmacists should evaluate vaccinations, medications prescribed, recognize drug-drug interactions, provide patient education, and monitor compliance. The team can thus improve outcomes for patients with cervical cancer. [level V]